ArticleCNS neuroscience & therapeutics2022
Hippocampal neuroprotection mediated by secretome of human mesenchymal stem cells against experimental stroke.
Article in CNS neuroscience & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Neuroprotective Effects of Conditioned Medium of Mesenchymal Stem Cells (MSC-CM) as a Therapy for Ischemic Stroke Recovery: A Systematic Review.Neurochemical research · 2023Pooled it
- Human Dental Pulp Stem Cell Secretome Restores Ischemic Stroke-Impaired Motor and Cognitive Functions by Reprogramming Redox and Inflammatory Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Human Umbilical Cord Mesenchymal Stem Cells Ameliorate Cognitive Decline by Restoring Senescent Microglial Function via NF-κB-SREBP1 Pathway Inhibition.Aging cell · 2025Article
- Reversing coma by senolytics and stem cells: the future is now.Journal of translational medicine · 2025Review
- Conditioned Medium of BMSCs Alleviates HMolecular neurobiology · 2025Article
- Sustaining Brain Youth by Neural Stem Cells: Physiological and Therapeutic Perspectives.Molecular neurobiology · 2025Review
- Effect of Cilostazol and Aspirin During Hyperacute Stroke Phase in Rats: An Experimental Research Study.Neurology international · 2025Article
- Reduce electrical overload via threaded Chinese acupuncture in nerve electrical therapy.Bioactive materials · 2025Article
- The Role of IL-6 in Ischemic Stroke.Biomolecules · 2025Review
- Effects of stem cell therapy on preclinical stroke.Open veterinary journal · 2025Review
- Article
- In vitro and In vivo Studies on Mesenchymal Stem Cells for Ischemic Stroke Therapy: A Scoping Review of The Therapeutic Effect.Stem cells and cloning : advances and applications · 2025Review
- Potential Mechanism and Perspectives of Mesenchymal Stem Cell Therapy for Ischemic Stroke: A Review.Global medical genetics · 2024Review
- Preconditioning of Mesenchymal Stem Cells Enhances the Neuroprotective Effects of Their Conditioned Medium in an Alzheimer's Disease In Vitro Model.Biomedicines · 2024Article
- Secretome Derived from Mesenchymal Stem/Stromal Cells: A Promising Strategy for Diabetes and its Complications.Current stem cell research & therapy · 2024Review
- Gens PSD-95 and GSK-3β expression improved by hair follicular stem cells-conditioned medium enhances synaptic transmission and cognitive abilities in the rat model of vascular dementia.Brain and behavior · 2024Article
- The Recent Applications of PLGA-Based Nanostructures for Ischemic Stroke.Pharmaceutics · 2023Review
- The Role of Mesenchymal Stromal Cells and Their Products in the Treatment of Injured Spinal Cords.Current issues in molecular biology · 2023Review
- Contemplating IL-6, a double-edged sword cytokine: Which side to use for stroke pathology?CNS neuroscience & therapeutics · 2023Review
- MicroRNA-140-5p inhibitor attenuates memory impairment induced by amyloid-ß oligomer in vivo possibly through Pin1 regulation.CNS neuroscience & therapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsRegenerative medicine literature has demonstrated that the therapeutic potentials of mesenchymal stem cells (MSCs) in experimental stroke are attributed to secreted bioactive factors rather than to cell replacement. Here, we explored the effects of secretome or conditioned medium (CM) derived from human embryonic stem cell-derived MSCs (hESC-MSCs) on hippocampal neurogenesis, inflammation, and apoptosis in experimental stroke.
methodsIschemic stroke was induced by right middle cerebral artery occlusion (MCAO) in male Wistar rats, and CM was infused either one time (1-h post-stroke; CM1) or three times (1-, 24-, and 48-h post-stroke; CM3) into left lateral ventricle. Neurogenesis markers (Nestin, Ki67, Doublecortin, and Reelin) were assessed at transcript and protein levels in the dentate gyrus of the hippocampus on day seven following MCAO. In parallel, changes in the gene expression of markers of apoptosis (Bax and Bim, as well as an anti-apoptotic marker of Bcl2), inflammation (IL-1β and IL-6, as well as IL-10 as an anti-inflammatory cytokine), trophic factors (BDNF, GDNF, NGF, and NT-3), and angiogenesis (CD31 and VEGF) in the hippocampus were assessed.
resultsOur results demonstrate that CM3 treatment could stimulate neurogenesis and angiogenesis concomitant with inhibition of inflammation, apoptosis, and neuronal loss in ischemic brains. Furthermore, rats treated with CM3 exhibited upregulation in neurotrophic factors.
conclusionOur results suggest that hESC-MSC-CM could promote neurogenesis and protect brain tissue from ischemic injury, partly mediated by induction of angiogenesis and neurotrophic factors and inhibition of inflammatory and apoptotic factors expression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.